Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

General Anxiety Disorder Clinical Trial

Official title:
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder

Status Completed

Clinical Trial Summary

To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00233675
Study type	Interventional
Source	Teva Branded Pharmaceutical Products R&D, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	August 2003

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01983033` - Training Protocol 'Drop it'. The Impact of a Training Protocol Focused on Coping With Negative Repetitive Thinking on Cognitive and Behavioural Functioning of People Suffering From GAD or Minor or Moderate Depressive Disorder or Depressive Disorder in Remission	N/A
Recruiting	`NCT04990492` - Interactive Voice Based Administration of the GAD 7	N/A
Recruiting	`NCT03084042` - Emotional Brain Networks & Cognitive Functioning in Depression and Anxiety
Completed	`NCT01931644` - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions